New Data Could Boost Potential Approval of Zogenix's Epilepsy Drug

Shares of Zogenix are climbing this morning after the California-based company posted new positive data for its investigational drug Fintepla in Dravet syndrome, a rare type of epilepsy. The new data could boost the company’s chances of securing regulatory approval.